Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1

NCT00036634 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00036634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2002
Completion date
February 28, 2003
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections